Association between B vitamins supplementation and risk of cardiovascular outcomes: A cumulative meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zhang, Chi ^a   Wang, Zhi Yong ^b   Qin, Ying Yi ^c   Yu, Fei Fei ^c   Zhou, Yu Hao ^a  

^a SHANGHAI SEVENTH PEOPLE S HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PLACEBO; PYRIDOXINE; THIAMINE; VITAMIN B GROUP; PROTECTIVE AGENT; VITAMIN B COMPLEX;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; INTERVENTION STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; ADVERSE EFFECTS; AGED; CARDIOVASCULAR DISEASES; DIET SUPPLEMENTATION; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 84907187090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107060     Document Type: Article

References (60)

1. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, et al. (1998) Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related geneitic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 98: 204-210.
2. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, et al. (1997) Plasma total homocysteine, B vitamins, and risk of atherosclerosis. Arterioscler Thromb Vasc Biol 17: 985-995.
3. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, et al. (1997) Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 96: 412-7.
4. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, et al. (2000) Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian, Asian and European men. Lancet 355: 523-527.
5. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, et al. (1995) Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 92: 2825-2830.
6. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, et al. (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346: 1395-1398.
7. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, et al. (1999) Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 159: 38-44.
8. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, et al. (1997) Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 54: 1276-1282.
9. The Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022.
10. Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 316: 894-898.
11. Homocysteine Lowering Trialists' Collaboration (2005) Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 82: 806-812.
12. Bazzano LA, Reynolds K, Holder KN, He J (2006) Effect of folic acid supplementation on risk of cardiovascular diseases a meta-analysis of randomized controlled trials. JAMA 296: 2720-2726.
13. Zhou Y-H, Tang J-Y, Wu M-J, Lu J, Wei X, et al. (2011) Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and metaanalysis. PLoS ONE 6: e25142.
14. Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, et al. (2012) The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 344: e3533.
15. Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, et al. (2012) Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 108: 400-7.
16. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, et al. (2010) Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 170: 1622-31.
17. Miller ER, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, et al. (2010) Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol 106: 517-27.
18. C Zhang, FL Chi, TH Xie, YH Zhou (2013) Effect of B-vitamin Supplementation on Stroke: a Meta-Analysis of Randomized Controlled Trials. PLoS One 8: e81577.
19. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876-82.
20. Baker F, Picton D, Blackwood S, Hunt J, Erskine M, et al. (2002) Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial [abstract]. Circulation (suppl 2): 741S.
21. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM (2002) Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 288: 973-979.
22. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, et al. (2004) Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA 291: 565-575.
23. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, et al. (2004) Folic Acid on Risk Diminishment After Acute Myocarial Infarction Study Group. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 93: 175-179.
24. Lange H, Suryapranata H, De Luca G, Börner C, Dille J, et al. (2004) Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673-2681.
25. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ (2005) Secondary prevention with folic acid: results of the Goes extension study. Heart 91: 1213-1214.
26. The NORVIT Trial Investigators (2006) Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. N Engl J Med 354: 1578-88.
27. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. N Engl J Med 354: 1567-77.
28. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, et al. (2008) Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography A Randomized Controlled Trial. JAMA 300: 795-804.
29. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors A Randomized Trial. JAMA 303: 2486-2494.
30. The SU.FOL.OM3 Collaborative Group (2010) Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled Trial. BMJ 341: c6273.
31. The VITATOPS Trial Study Group (2010) B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9: 855-65.
32. Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, et al. (2003) Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 9: PI19-PI24.
33. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, et al. (2004) Randomized trial of folic acid for prevention of cardiovascular events in endstage renal disease. J AmSoc Nephrol 15: 420-426.
34. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, et al. (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 47: 1108-1116.
35. Righetti M, Serbelloni P, Milani S, Ferrario G (2006) Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24: 379-386.
36. Vianna ACA, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, et al. (2007) Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodialysis International 11: 210-216.
37. The Polyp Prevention Study Group (2007) Folic Acid for the Prevention of Colorectal Adenomas A Randomized Clinical Trial. JAMA 297: 2351-2359.
38. The Veterans Affairs Site Investigators (2007) Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease A Randomized Controlled Trial. JAMA 298: 1163-1170.
39. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, et al. (2008) Effect of Folic Acid and B-Vitamins on Risk of Cardiovascular Events and Total Mortality among Women at High Risk for Cardiovascular Disease: A Randomized Trial. JAMA 299: 2027-2036.
40. The BVAIT Research Group (2009) High-Dose B Vitamin Supplementation and Progression of Subclinical Atherosclerosis A Randomized Controlled Trial. Stroke 40: 730-736.
41. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, et al. (2010) Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy A Randomized Controlled Trial. JAMA 303: 1603-1609.
42. Heinz J, Kropf S, Domröse U, Westphal S, Borucki K, et al. (2010) B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal Disease: Results of a Randomized Controlled Trial. Circulation 121: 1432-1438.
43. The FAVORIT Study Group (2011) Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Circulation 123: 1763-1770.
44. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Medicine 6: e1000097.
45. Jadad AR, Moore RA, Carroll D (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
46. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-88.
47. Ades AE, Lu G, Higgins JP (2005) The interpretation of random-effects metaanalysis in decision models. Med Decis Making 25: 646-54.
48. Deeks JJ, Higgins JPT, Altman DG (2008) Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration: chap 9.
49. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-60.
50. Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21: 1559-73.
51. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
52. Tobias A (1999) Assessing the influence of a single study in meta-analysis. Stata Tech Bull 47: 15-17.
53. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34.
54. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
55. Lee M, Hong KS, Chang SC, Saver JL (2010) Efficacy of Homocysteine-Lowering Therapy With Folic Acid in Stroke Prevention: A Meta-Analysis. Stroke 41: 1205-1212.
56. Ji Y, Tan S, Xu Y, Chandra A, Shi C, et al. (2013) Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: A meta-analysis. Neurology 81: 1-10.
57. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S (1999) Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131: 363-375.
58. Loscalzo J (2006) Homocysteine trials: clear outcomes for complex reasons. N Engl J Med 354: 1629-1632.
59. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, et al. (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-81.
60. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, et al. (2011) Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 378: 584-94.